#USA #Palo Alto #Immunotherapy #Riboscience #RBS2418

Encouraging Results for RBS2418 in Advanced Cancer Treatments

In a groundbreaking presentation at the European Society for Medical Oncology (ESMO) Congress 2026 held in Madrid, Spain, Riboscience, a clinical-stage biotechnology firm, announced significant findings from the Phase 1a/b clinical trial of their oral ENPP1 inhibitor, RBS2418. This new therapeutic approach is showing potential for improving overall survival rates in patients suffering from advanced solid tumors, particularly in those with late-line metastatic colorectal cancer (mCRC).

Study Overview

The study included data from 81 heavily pretreated subjects with metastatic solid tumors, around 49 of whom received RBS2418 as a standalone treatment. Simultaneously, a subset of 27 participants received RBS2418 in combination with pembrolizumab, while a further five received it alongside other approved cancer therapies. The trial specifically focused on tumors expressing ENPP1 and cGAS proteins, denoting a TME-EG+ phenotype.

The results demonstrated a median overall survival (OS) of 12 months for those receiving monotherapy with RBS2418 compared to just 4.2 months for individuals whose tumors lacked the TME-EG+ feature, with statistical significance observed (p=0.0022). Notably, a subgroup analysis highlighted a median OS of 14 months among patients with late-line mCRC, a considerably challenging cohort considering that around 74% had liver metastases at baseline. This achievement marks a crucial leap forward in a patient population where treatment options are severely limited and survival rates are historically low.

Safety and Tolerability

RBS2418 was well-tolerated by the participating subjects, with no reports of serious adverse events linked to the treatment. About 64% of the patients experienced negligible treatment-related side effects, classified as Grade 1 or lower. Adverse events categorized as Grade 2 and 3 were recorded in 19% and 2.2% of subjects, respectively, pointing towards an overall positive safety profile for this investigational drug.

Immune Activation Insights

An intriguing aspect of the trial was the association of prolonged overall survival with significant intratumoral immune activation in participants. RBS2418 treatment correlated with marked increases in the infiltration of activated immune cells, specifically CD4+ and CD8+ T cells, crucial for effective antitumor responses. The pharmacodynamic responses also indicated that RBS2418 maintained serum levels of cGAMP—a vital immune signaling molecule—while preventing the rise of pyrophosphate levels linked to ENPP1 activity. This response suggests that RBS2418 effectively restores immune activation capabilities within the tumor microenvironment.

Next Steps for Development

Encouraged by these results, Riboscience is continuing to investigate RBS2418's therapeutic potential. The drug is currently being evaluated in two Phase 2 trials: one focusing on its role as a monotherapy for late-line mCRC and the other examining its efficacy alongside the STRIDE regimen (tremelimumab and durvalumab) for hepatocellular carcinoma.

RBS2418, notable for being a first-in-class ENPP1 inhibitor, aims to counteract immune evasion behaviors frequently observed in various solid tumors. By inhibiting the ENPP1 enzyme, RBS2418 seeks to not only preserve critical immune activators like cGAMP but also, ideally, enhance the body's natural cancer-fighting capabilities.

Conclusion

The initial findings from the Phase 1a/b trial of RBS2418 highlight a promising new avenue for therapeutic intervention in cancer treatment, particularly for heavily pretreated patients with limited options. Riboscience's ongoing research efforts may pave the way for a next-generation treatment paradigm in oncology, marrying innovative pharmacology with the complexities of the immune response. As the clinical trials progress, the medical community remains optimistic about the potential of RBS2418 to change the landscape for patients battling advanced malignancies.